The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Earlier, Yahoo Finance discussed this stock as it revealed Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares.
Vaxcyte Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $74.15 and fluctuated between $75.05 as its day high and $72.76 as its day low. The current market capitalization of Vaxcyte Inc is $7.87B. A total of 1.28 million shares were traded on the day, compared to an average of 824.05K shares.
Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, PCVX has seen 3 BUY and 3 SELL insider trades, representing the acquisition of 23,025 and the disposition of 18,125 shares. Over the last 12 months, there were 22 BUYs and 39 SELLs from insiders. Insiders purchased 205,400 shares during that period but sold 117,532.
In the most recent transaction, Wassil Jim sold 3,000 shares of PCVX for 73.88 per share on Feb 01. After the transaction, the CHIEF OPERATING OFFICER now owns 175,935 company shares. In a previous transaction on Feb 01, PICKERING GRANT sold 2,616 shares at 73.91 per share. PCVX shares that CHIEF EXECUTIVE OFFICER owns now total 149,978.
Among the insiders who sold shares, Eydelman Mikhail disposed of 1,667 shares on Feb 01 at a per-share price of $73.87. This resulted in the SVP, GEN COUNSEL & CORP SEC holding 20,710 shares of PCVX after the transaction. In another insider transaction, Lukatch Heath sold 5,000 shares at $71.50 per share on Jan 31. Company shares held by the Director now total 5,625.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. In terms of 52-week highs and lows, PCVX has a high of $75.84 and a low of $34.11.
As of this writing, PCVX has an earnings estimate of -$1.15 per share for the current quarter. EPS was calculated based on a consensus of 7 estimates, with a high estimate of -$0.99 per share and a lower estimate of -$1.61. The company reported an EPS of -$0.7 in the last quarter, which was 5.40% higher than expectations of -$0.74.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. PCVX’s latest balance sheet shows that the firm has $245.97M in Cash & Short Term Investments as of fiscal 2021. There were $16.78M in debt and $28.72M in liabilities at the time. Its Book Value Per Share was $14.75, while its Total Shareholder’s Equity was $284.02M.
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for PCVX is Buy with a score of 4.89.